Skip to main content

Report: NFL Tried to Influence NIH-Supported Concussion Study

A Congressional investigation indicates that the National Football League may have sought to steer millions of dollars in National Institutes of Health funding away from one of its critics.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

WIKIMEDIA, RON ALMOGAccording to a report authored by Democrats in the U.S. House of Representatives, officials at the National Football League (NFL) “improperly attempted to influence” how the National Institutes of Health (NIH) awarded funds to fuel research on traumatic brain injury. At issue is $16 million that was part of a $30 million supposedly no-strings-attached donation that the NFL made to the Foundation for the NIH (FNIH) that was supposed to fund research into concussion and other brain trauma in 2013.

In 2014, the NIH put out a call for proposals for the $16 million grant to study chronic traumatic encephalopathy, eventually selecting one from Boston University (BU) researcher Robert Stern. Now, in their report released Monday (May 23), Democrats on the House Committee on Energy and Commerce have alleged that NFL officials contacted the FNIH and voiced their displeasure with Stern—who had been openly critical of the league’s handling of head injury-related neuropsychological testing in prior lawsuits—having received the grant.

“There are many of us who have significant concerns re BU and their ability to be unbiased and collaborative,” Elliot Pellman, former chair of the NFL’s defunct mild traumatic brain injury committee and currently a medical administrator for the league, wrote in an email to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Related Topics

Related articles background image
The Scientist Digest cover September 2026
September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue
Essential Genes Are Dominantly Activated by Single Transcription Factors

Essential Genes Are Dominantly Activated by Single Transcription Factors

EpiCypher Logo
Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Alamar Biosciences logo
Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Engineering CAR-Neutrophils In Vivo to Target Glioblastoma

Miltenyi
Best Practices for qPCR Assay Design and Optimization

Best Practices for qPCR Assay Design and Optimization

Bio-Rad

Products

Closeup image of a multi channel pipette dispensing pink liquid into a 96-well plate.

The ASSIST PLUS pipetting robot for affordable workflow automation

Integra Logo
Single cells in suspension

Rapidly isolate primary cells and make uniform single-cell suspensions with Corning® Cell Strainers

Corning logo
Abstract image representing cell membranes linked together.

CellBrite® Steady Membrane Stain: Cell surface staining built for real-time imaging

Biotium
sino biological logo

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays